Aduhelm represents a significant step forward in the treatment of Alzheimer’s disease, with its advanced effects and benefits making it an exciting development in the field of Alzheimer’s research.
The drug offers hope to millions of people worldwide suffering from Alzheimer’s disease,
Amondys 45 (casimersen) is an FDA-approved medication that can potentially improve the quality of life of DMD patients who have a specific mutation in exon 45 of the dystrophin gene.
Amondys 45 works by inducing exon skipping and promoting the production of truncated dystrophin, which can partially restore muscle function in affected individuals.
Fleqsuvy (baclofen) is a medication used for the treatment of people with spasticity from multiple sclerosis (MS) or people with certain injuries to the spine.
Mavenclad is a new and promising treatment option for relapsing forms of multiple sclerosis.
The drug has several advantages, including its advanced effects on reducing relapse frequency, delaying relapse time, slowing down MS progression, and having a unique dosing regimen.
Neupro patch is a promising advancement in the treatment of Parkinson’s disease.
Its continuous and convenient delivery of medication, along with its ability to improve both motor and non-motor symptoms, makes it a valuable option for patients and healthcare professionals alike.
Ocrevus (ocrelizumab) is a biologic drug that has revolutionized the treatment of MS.
Its ability to selectively target and eliminate B cells has shown impressive efficacy in slowing down the progression of this debilitating disease. 1 vial of 300 mg/mL
Ponvory (ponesimod) is an advanced medication that offers a promising treatment option for relapsing MS.
It effectively suppresses inflammatory immune cells and promotes neuroprotection, leading to a reduction in relapse rates and potential neuroprotective benefits.
Tecfidera (dimethyl fumarate) is an oral medication that is used to treat multiple sclerosis in adults.
It works by reducing inflammation in the central nervous system, which can help to reduce MS relapses and slow down the progression of disability. 56 capsules of 240 mg
Wakix represents a significant advance in the treatment of narcolepsy and other sleep disorders.
Its unique mechanism of action, low risk of side effects, and ability to treat both excessive daytime sleepiness and cataplexy make it a valuable treatment option for people with narcolepsy who have not responded well to other treatments.